Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs
暂无分享,去创建一个
[1] Gordon L. Amidon,et al. Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model , 1993, Pharmaceutical Research.
[2] D. Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). , 2006, Journal of pharmaceutical sciences.
[3] Jack A. Cook,et al. Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond , 2008, The AAPS Journal.
[4] D. Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. , 2006, Journal of pharmaceutical sciences.
[5] Anders Karlén,et al. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. , 2003, Journal of molecular graphics & modelling.
[6] S. Kopp. PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE REQUIREMENTS FOR THE WHO MODEL LIST OF ESSENTIAL MEDICINES IMMEDIATE RELEASE, SOLID ORAL DOSAGE FORMS , 2005 .
[7] Hans Lennernäs,et al. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension , 2005, The Journal of pharmacy and pharmacology.
[8] A. Hoffman,et al. Enhanced Gastrointestinal Absorption of Lipophilic Drugs , 2006 .
[9] M. Sherry Ku,et al. Use of the Biopharmaceutical Classification System in Early Drug Development , 2008, The AAPS Journal.
[10] A. Dahan,et al. Food–drug interaction: grapefruit juice augments drug bioavailability—mechanism, extent and relevance , 2004, European Journal of Clinical Nutrition.
[11] G L Amidon,et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.
[12] Leslie Z Benet,et al. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.
[13] M. Bermejo,et al. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] B. Schug,et al. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] Lawrence X. Yu,et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. , 2006, Molecular pharmaceutics.
[16] Vinod P. Shah,et al. The Use of BDDCS in Classifying the Permeability of Marketed Drugs , 2008, Pharmaceutical Research.
[17] R. Löbenberg,et al. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards , 2000 .
[18] Lawrence X. Yu,et al. The use of drug metabolism for prediction of intestinal permeability (dagger). , 2009, Molecular pharmaceutics.
[19] Nipa Shah,et al. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. , 2009, Molecular pharmaceutics.
[20] H Lennernäs,et al. Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.
[21] Lawrence X. Yu,et al. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. , 2005, Molecular pharmaceutics.
[22] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[23] G. Amidon,et al. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. , 2006, Molecular pharmaceutics.
[24] G. Amidon,et al. Gastrointestinal Dissolution and Absorption of Class II Drugs , 2008 .
[25] G. Amidon,et al. The H2 Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport , 2009, The AAPS Journal.
[26] J. Polli. In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms , 2008, The AAPS Journal.
[27] Lawrence X. Yu,et al. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. , 2004, Molecular pharmaceutics.
[28] S. Yamashita,et al. Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products. , 2009, Molecular pharmaceutics.
[29] Mei-Ling Chen,et al. Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. , 2004, Journal of pharmaceutical sciences.
[30] Vinod P. Shah,et al. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.
[31] G. Amidon,et al. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[32] Lawrence X. Yu,et al. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.
[33] G. Amidon,et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.
[34] H Lennernäs,et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.
[35] John M Hilfinger. BCS in drug discovery, development, and regulation. , 2009, Molecular pharmaceutics.
[36] W. Addicks,et al. Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View , 2008, The AAPS Journal.
[37] J. Kuhlmann,et al. Guidances related to bioavailability and bioequivalence: European industry perspective , 2010, European Journal of Drug Metabolism and Pharmacokinetics.
[38] D. Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: amitriptyline hydrochloride. , 2006, Journal of pharmaceutical sciences.
[39] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[40] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[41] Han van de Waterbeemd,et al. Drug bioavailability : estimation of solubility, permeability, absorption and bioavailability , 2003 .
[42] Jennifer B Dressman,et al. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[43] L. Benet,et al. Net Secretion of Furosemide Is Subject to Indomethacin Inhibition, as Observed in Caco-2 Monolayers and Excised Rat Jejunum , 1999, Pharmaceutical Research.
[44] S. Stavchansky. Scientific Perspectives on Extending the Provision for Waivers of In vivo Bioavailability and Bioequivalence Studies for Drug Products Containing High Solubility-Low Permeability Drugs (BCS-Class 3) , 2008, The AAPS Journal.
[45] Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I). , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[46] Jelena Parojcić,et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. , 2009, Molecular pharmaceutics.
[47] Lawrence X. Yu,et al. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. , 2007, Molecular pharmaceutics.
[48] J. Proudfoot,et al. Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. , 2006, Journal of pharmaceutical sciences.
[49] Jennifer B Dressman,et al. Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products , 2006, Clinical Pharmacokinetics.
[50] B. W. Barry,et al. Enhancement in Drug Delivery , 2006 .
[51] Lawrence X. Yu,et al. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.